SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential inclusion in the Russell 1000 index, driving significant options activity and ongoing conflict between bullish sentiment and short sellers. The community remains focused on the long-term potential of its immunotherapy platform, Anktiva, while actively discussing clinical progress, upcoming commercialization milestones, and institutional positioning.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending as investors weigh an upcoming earnings report against a backdrop of deep structural declines, leadership changes, and heavy selling pressure. The community is sharply divided, with some buyers viewing the stock as a long-term value play akin to previous turnaround stories, while others remain bearish due to persistent market share losses and negative sentiment toward management's communication style.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors weigh potential regulatory and legal catalysts, specifically a pending FDA decision and an ongoing distribution dispute with partner Nippon Shinyaku. The community remains actively engaged in discussions regarding the strength of clinical trial data, the implications of upcoming court hearings, and the long-term potential for label expansion into broader muscular dystrophy indications.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is trending as retail investors and community members coordinate a massive push, fueling speculation of a short squeeze aimed at trapping institutions with high short interest. Participants are rallying around the brand's low valuation and dividend yield, urging others to hold shares tightly to force a rapid move toward double-digit price levels.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as retail investors voice frustration over persistent, low-volume price swings that many describe as market manipulation. Community discussion remains heavily focused on the stock's volatility and its challenging technical performance compared to broader market trends.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is facing significant market volatility and investor skepticism following the announcement of an all-stock acquisition of Synaptics, with community members debating the risks of dilution versus the long-term potential of expanding into edge AI and robotics. While some traders are viewing the pullback as a buying opportunity, others are wary of the deal's complexity and are bracing for further consolidation as the stock seeks a new price floor.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors weigh recent expansion news and strategic AI-networking partnerships against heavy options-related volatility. The community remains focused on whether Nokia can successfully transition into a critical AI infrastructure play, with many using the stock's recent price fluctuations as a buying opportunity ahead of upcoming earnings.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing heightened social media buzz and active community speculation regarding its potential for a massive short squeeze, driven by a tight tradable float and aggressive corporate share buybacks. Traders are closely monitoring elevated short interest and specific technical levels, debating whether these fundamentals can trigger a parabolic move while the stock consolidates.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing intense volatility driven by speculative frenzy and heavy institutional interest surrounding the memory and storage supercycle tied to AI infrastructure demand. The community is sharply divided, with bulls betting on sustained sector growth and potential price target upgrades, while bears warn of a classic bubble cycle and imminent overextension.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors weigh the EMA's negative opinion on narsoplimab against the company's commitment to a re-examination procedure and its solid U.S. market position. While the community is actively debating the credibility of EMA's regulatory process and questioning management's communication strategy, many are focused on the upcoming J-Code activation and the potential for an independent expert review to trigger a reversal in sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation PR Newswire LONDON, June 24, 2026 LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that...

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes PR Newswire LONDON, May 26, 2026 LONDON, May 26...

Why Is Virax Biolabs (VRAX) Stock Trending Overnight?

Virax Biolabs Group Limited shares rose 17.36% after hours following heavy intraday gains and disclosure of a new 4.99% hedge fund stake.read more...

Nasdaq Down 200 Points; Brady Earnings Top Views

US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...

Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders

Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones...

Breakthrough Science, AI Deals, and Nasdaq Warnings Collide in a High-Stakes Market Surge

A volatile mix of scientific breakthroughs, aggressive expansion, fresh capital inflows, and compliance risks is defining the current small- and micro-cap landscape. $KBLB, $RMSG, $VRAX, $ALMU, $IMA, $RCT, $NTRA, $ALLO, $RECT, $FFAI

AI and Biotech Enter a Stock Picker’s Market

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

What's Behind The Jump In Virax Biolabs Stock?

Shares of Virax Biolabs Group are soaring Tuesday after it secured several regulatory certifications paving the way for clinical validation.read more...

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD...

Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why

Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Ltd - Ordinary Shares - Class A

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.86
Prev Close	$3.38
Open	$3.12
Dividend Yield	0.00%
50-Day Moving Average	$4.40
Beta	0.92
Avg. Volume	2.16M
PE Ratio	-2.70

52-Week High	$28.50
52-Week Low	$2.50
Market Capitalization	$2.69M
EPS (Annual)	-$1.62
Price to Book	4.16
Revenue Per Employee	$333.21

Feed

News

Sentiment

Fundamentals

Info

VRAXVirax Biolabs Group Ltd

Latest VRAX News